Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by Kirtapmlaon Aug 02, 2016 4:41pm

148 Views

Post# 25103907

RE:Teva / Allergan deal completed

Great news IF Allergan is our future partner. If so I see know reason for them only to sign a deal with an upfront payment, my gut feeling are more leaning towards buyout of 1067 or the whole company.

Now it's up to Sirona to show us what they are made of. Can they create the results to their shareholders as we all are hoping for?

Bullboard Posts

dynaCERT leans into global growth with new HydraGEN orders